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the three “Musketairs” – lasker Prize 2016 goes 
to the protagonists of hypoxia research
roland H Wenger1
dörthe M Katschinski2
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Zurich, Zurich, Switzerland; 2institute 
of Cardiovascular Physiology, 
Georg-august University Göttingen, 
Göttingen, Germany
Who does not know them? One bearded like a pirate, one knighted by the Queen, 
and one of noble spirit. United in the fight for truth and honor! No, this is not about 
 Alexandre Dumas’ characters Porthos, Athos, and Aramis, well-known from the famous 
novel The Three Musketeers.1 This is about the most recent awardees of the Albert 
Lasker Basic Medical Research Award, the three protagonists of hypoxia research 
Gregg Semenza, Sir Peter Ratcliffe, and Bill Kaelin. The recent bestowal of the Lasker 
Prize is just another hallmark in a long list of recognitions of the major achievements 
by these three outstanding colleagues. What major victories in the battle against the 
unknowns in hypoxia research did our three heroes achieve?
Undoubtedly, Gregg Semenza initiated the hypoxia tale by cloning, together with his 
combatant Guang L Wang, the hypoxia-inducible factor. Following his initial descrip-
tion in 1992 of a unique hypoxia-inducible band in electrophoretic mobility shift assay 
(EMSA)2, designated hypoxia-inducible factor (HIF), many tried to unravel the nature 
of this protein binding to the erythropoietin 3’-hypoxia response element. But it was 
not until 1995 that Wang and Semenza succeeded in identifying HIF as a heterodi-
mer consisting of a known protein (HIF-1β or ARNT) and a novel hypoxia-inducible 
protein (HIF-1α).3 Their cloning attack followed a classical but tedious strategy: 
purifying the activity from hundreds of liters of cell culture and using EMSA to trace 
the suspect. All the many other sophisticated strategies devised by competing groups 
basically failed. Nevertheless, the finding that HIF regulates not only erythropoietin 
but hundreds of other target genes4,5 attracted the attention of many other kingdoms, 
which then entered the hypoxia battlefield, with “oncology” at the forefront. It quickly 
became clear that the crucial step in hypoxia-inducible gene expression is the oxygen-
dependent destabilization of the HIFα subunit. But how oxygen interacted with HIFα 
remained a mystery well protected from the sorcerers of the invading kingdoms. Many 
mysterious molecular saboteurs were under suspicion, such as mitochondria, reactive 
oxygen species, redox state, general metabolism, and so on, but none of them could 
be arrested for HIFα destruction (reviewed by Wenger6).
This is when Sir Peter Ratcliffe and his men, including Patrick H Maxwell and 
Chris W Pugh, struck out for their first victory. By using a powerful weapon (antibodies 
against HIF-2α), still difficult to forge nowadays, they hunted down a tumor suppressor 
protein, known as “von Hippel-Lindau” (pVHL), guilty of oxygen- and iron-mediated 
HIFα demolition.7 Other strategies were blunt swords in this battle, because antibodies 
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against HIF-1α proved futile in studies using pVHL-deficient 
renal cancer cell lines, simply because many of these cell 
lines initially contained supramaximal toxic HIF-1α levels, 
which cancer selects against and instead selects for HIF-2α 
expression.8 This seminal discovery of the E3 ligase pVHL, 
targeting HIFα for polyubiquitination and proteasomal deg-
radation, finally provided the long-sought-for magic bullet 
that allowed the differentiation between hypoxic (nonmodi-
fied) and normoxic (modified) HIFα, because pVHL stably 
interacts with HIFα only under conditions compatible with 
the presence of an enzymatic activity that is oxygen- and 
iron-dependent.
Once the front lines were set, the events were overturning. 
The alliance between the mighty forces led by Bill Kaelin 
on one side, and with Sir Peter Ratcliffe and his men on the 
other side, quickly resolved the covalent modification of 
HIFα, which serves as recognition interface between HIFα 
and pVHL: oxygen derived from atmospheric air is used to 
hydroxylate two prolyl residues in the oxygen-dependent 
degradation domain of HIFα – a truly elegant and simple 
mechanism to combine oxygen sensing with signal trans-
duction.9,10 What was remaining was the identification of the 
responsible enzyme(s), but the resistance to reveal this final 
secret was weak. Sir Peter Ratcliffe struck out for his second 
and final victory by employing a heretofore unknown fairy 
army hidden only a few steps away from his headquarters. 
With the help of the simple genetics of these almost invisible 
creatures (known to the informed world as Caenorhabditis 
elegans), a new family of enzymes could be identified which 
use oxygen and 2-oxoglutarate as cosubstrates to hydroxyl-
ate HIFα subunits and to produce succinate by oxidative 
decarboxylation of 2-oxoglutarate in an iron- and reducing-
agents-dependent process.11
During the following years, many scientists and com-
panies were attracted by the shining lights of the treasures 
uncovered by Semenza, Ratcliffe, and Kaelin. Their findings 
fill libraries with more than 14,000 publications on HIF (and 
over 133,000 publications on hypoxia in general). Clinical 
trials are currently conducted, and it is likely that patients 
will soon profit from these amazing discoveries, a fact that 
was certainly also contributing to the decision to honor the 
Three “Musketairs” with the Lasker Prize.
The fandom is looking forward to the next chapters of the 
hypoxia saga to be written by our three heroes.
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